{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:19:35Z","timestamp":1785766775832,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40263-020-00775-9","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T15:37:53Z","timestamp":1606145873000},"page":"1275-1286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study"],"prefix":"10.1007","volume":"34","author":[{"name":"Dimethyl Fumarate Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Pilo de la Fuente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sab\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Thuissard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Sainz de la Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Costa-Frossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra","family":"G\u00f3mez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"D\u00edaz-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lozano-Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Garc\u00eda-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Ayuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Meca-Lallana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"L\u00f3pez de Silanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rodr\u00edguez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Andreu-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"Garc\u00eda-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9459-5452","authenticated-orcid":false,"given":"Yolanda","family":"Aladro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"issue":"13","key":"775_CR1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2377-13-128","volume":"26","author":"E Kingwell","year":"2013","unstructured":"Kingwell E, Marriott JJ, Jett\u00e9 N, Pringsheim T, Makhani N, Morrow SA, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013;26(13):128. https:\/\/doi.org\/10.1186\/1471-2377-13-128.","journal-title":"BMC Neurol."},{"issue":"10130","key":"775_CR2","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(18)30481-1.","journal-title":"Lancet"},{"key":"775_CR3","first-page":"15","volume-title":"Handbook of clinical neurology","author":"A Kutzelnigg","year":"2014","unstructured":"Kutzelnigg A, Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. In: Aminoff MJ, Boller F, Swaab DF, editors. Handbook of clinical neurology. Amsterdam: Elsevier BV; 2014. p. 15\u201358."},{"key":"775_CR4","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1212\/NXI.0000000000000508","volume":"6","author":"E Staun-Ram","year":"2018","unstructured":"Staun-Ram E, Najjar E, Volkowich A, Miller A. Dimethyl fumarate as a first- vs second-line therapy in MS: focus on B cells. Neurol Neuroimmunol Neuroinflamm. 2018;6:e508. https:\/\/doi.org\/10.1212\/NXI.0000000000000508.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"775_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fneur.2018.00005","volume":"9","author":"EA Mills","year":"2018","unstructured":"Mills EA, Ogrodnik MA, Plave A, Mao-Draayer Y. Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol. 2018;9:5. https:\/\/doi.org\/10.3389\/fneur.2018.00005.","journal-title":"Front Neurol."},{"issue":"7","key":"775_CR6","doi-asserted-by":"publisher","first-page":"9943","DOI":"10.1002\/jcp.27930","volume":"234","author":"A Hosseini","year":"2019","unstructured":"Hosseini A, Masjedi A, Baradaran B, Hojjat-Farsangi M, Ghalamfarsa G, Anvari E, et al. Dimethyl fumarate: regulatory effects on the immune system in the treatment of multiple sclerosis. J Cell Physiol. 2019;234(7):9943\u201355. https:\/\/doi.org\/10.1002\/jcp.27930.","journal-title":"J Cell Physiol."},{"issue":"7","key":"775_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/brainsci7070078","volume":"7","author":"N Dargahi","year":"2017","unstructured":"Dargahi N, Katsara M, Tselios T, Androutsou ME, de Courten M, Matsoukas J, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci. 2017;7(7):78. https:\/\/doi.org\/10.3390\/brainsci7070078.","journal-title":"Brain Sci."},{"issue":"1","key":"775_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2174\/157015909787602788","volume":"7","author":"D Moharregh-Khiabani","year":"2009","unstructured":"Moharregh-Khiabani D, Linker RA, Gold R, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol. 2009;7(1):60\u20134. https:\/\/doi.org\/10.2174\/157015909787602788.","journal-title":"Curr Neuropharmacol."},{"issue":"1","key":"775_CR9","doi-asserted-by":"publisher","first-page":"8194","DOI":"10.1038\/s41598-018-26519-w","volume":"8","author":"G Montes Diaz","year":"2018","unstructured":"Montes Diaz G, Fraussen J, Van Wijmeersch B, Hupperts R, Somers V. Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients. Sci Rep. 2018;8(1):8194. https:\/\/doi.org\/10.1038\/s41598-018-26519-w.","journal-title":"Sci Rep."},{"issue":"12","key":"775_CR10","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"67","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;67(12):1098\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1114287.","journal-title":"N Engl J Med."},{"issue":"12","key":"775_CR11","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1206328.","journal-title":"N Engl J Med."},{"issue":"2","key":"775_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1352458516649037","volume":"23","author":"R Gold","year":"2017","unstructured":"Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017;23(2):253\u201365. https:\/\/doi.org\/10.1177\/1352458516649037.","journal-title":"Mult Scler."},{"issue":"1","key":"775_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40120-016-0042-8","volume":"5","author":"R Gold","year":"2016","unstructured":"Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL. Sustained effect of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies. Neurol Ther. 2016;5(1):45\u201357. https:\/\/doi.org\/10.1007\/s40120-016-0042-8.","journal-title":"Neurol Ther."},{"issue":"1","key":"775_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12883-018-1220-3","volume":"19","author":"T Saida","year":"2019","unstructured":"Saida T, Yamamura T, Kondo T, Yun J, Yang M, Li J, et al. A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries. BMC Neurol. 2019;19(1):5. https:\/\/doi.org\/10.1186\/s12883-018-1220-3.","journal-title":"BMC Neurol."},{"issue":"10","key":"775_CR15","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40263-018-0543-3","volume":"32","author":"M Mirabella","year":"2018","unstructured":"Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: an Italian, multicenter, real-world study. CNS Drugs. 2018;32(10):963\u201370. https:\/\/doi.org\/10.1007\/s40263-018-0543-3.","journal-title":"CNS Drugs"},{"issue":"8","key":"775_CR16","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1007\/s00415-018-8916-6","volume":"265","author":"G Mallucci","year":"2018","unstructured":"Mallucci G, Annovazzi P, Miante S, Torri-Clerici V, Matta M, La Gioia S, et al. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. J Neurol. 2018;265(8):1850\u20139. https:\/\/doi.org\/10.1007\/s00415-018-8916-6.","journal-title":"J Neurol."},{"issue":"2","key":"775_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","volume":"13","author":"M Trojano","year":"2017","unstructured":"Trojano M, Tintore M, Montalban X, Hillert J, Kalincik T, Iaffaldano P, et al. Treatment decisions in multiple sclerosis-insights from real-world observational studies. Nat Rev Neurol. 2017;13(2):105\u201318. https:\/\/doi.org\/10.1038\/nrneurol.2016.188.","journal-title":"Nat Rev Neurol."},{"issue":"2","key":"775_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.nrl.2016.02.026","volume":"2","author":"A Garc\u00eda-Merino","year":"2017","unstructured":"Garc\u00eda-Merino A, Ara Callizo JR, Fern\u00e1ndez-Fern\u00e1ndez O, Landete Pascual L, Torres ME, Zarrantz ARA. Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016. Neurologia. 2017;2(2):113\u20139. https:\/\/doi.org\/10.1016\/j.nrl.2016.02.026.","journal-title":"Neurologia."},{"key":"775_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.106","author":"A Rovira","year":"2015","unstructured":"Rovira A, Wattjes MP, Tintor\u00e9 M, Tur C, Yousry TA, Sormani MP, et al. MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015. https:\/\/doi.org\/10.1038\/nrneurol.2015.106.","journal-title":"Nat Rev Neurol."},{"issue":"13","key":"775_CR20","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1177\/1352458516653667","volume":"22","author":"T Kalincik","year":"2016","unstructured":"Kalincik T, Butzkueven H. Observational data: understanding the real MS world. Mult Scler. 2016;22(13):1642\u20138. https:\/\/doi.org\/10.1177\/1352458516653667.","journal-title":"Mult Scler."},{"issue":"8","key":"775_CR21","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1007\/s00415-020-09848-7","volume":"267","author":"J Sabin","year":"2020","unstructured":"Sabin J, Urtiaga S, Pilo B, Thuissard I, Galan V, de la Maza SS, et al. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population. J Neurol. 2020;267(8):2362\u201371. https:\/\/doi.org\/10.1007\/s00415-020-09848-7.","journal-title":"J Neurol."},{"issue":"4","key":"775_CR22","doi-asserted-by":"publisher","first-page":"205521731988719","DOI":"10.1177\/2055217319887191","volume":"5","author":"T Berger","year":"2019","unstructured":"Berger T, Brochet B, Brambilla L, Giacomini PS, Montalb\u00e1n X, Vasco Salgado A, et al. Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC. Mult Scler J Exp Transl Clin. 2019;5(4):2055217319887191. https:\/\/doi.org\/10.1177\/2055217319887191.","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"775_CR23","unstructured":"Giles K, Balashov K, Jones CC, Macdonell R, Miller C, Windsheimer J, et al. Real-world efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: interim results from ESTEEM. In: ECTRIMS; 10-12 October 2018; Berlin. Paper no. P595. Switzerland: ECTRIMS."},{"issue":"12","key":"775_CR24","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1177\/1352458519866600","volume":"26","author":"M Granqvist","year":"2020","unstructured":"Granqvist M, Burman J, Gunnarsson M, Lycke J, Nilsson P, Olsson T, et al. Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. Mult Scler. 2020;26(12):1532\u20139. https:\/\/doi.org\/10.1177\/1352458519866600.","journal-title":"Mult Scler."},{"issue":"5","key":"775_CR25","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/ene.13272","volume":"24","author":"E Havrdova","year":"2017","unstructured":"Havrdova E, Giovannoni G, Gold R, Fox RJ, Kappos L, Phillips JT, et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol. 2017;24(5):726\u201333. https:\/\/doi.org\/10.1111\/ene.13272.","journal-title":"Eur J Neurol."},{"issue":"7","key":"775_CR26","doi-asserted-by":"publisher","first-page":"e635","DOI":"10.1212\/wnl.0000000000007938","volume":"93","author":"DA Laplaud","year":"2019","unstructured":"Laplaud DA, Casey R, Barbin L, Debouverie M, De S\u00e8ze J, Brassat D, et al. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019;93(7):e635\u201346. https:\/\/doi.org\/10.1212\/wnl.0000000000007938.","journal-title":"Neurology."},{"issue":"10","key":"775_CR27","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1007\/s00415-020-09959-1","volume":"267","author":"E D'Amico","year":"2020","unstructured":"D\u2019Amico E, Zangh\u00ec A, Sciandra M, Lanzillo R, Callari G, Cortese A, et al. Dimethyl fumarate vs teriflunomide: an Italian time-to-event data analysis. J Neurol. 2020;267(10):3008\u201320. https:\/\/doi.org\/10.1007\/s00415-020-09959-1.","journal-title":"J Neurol."},{"issue":"12","key":"775_CR28","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1007\/s00415-018-9083-5","volume":"265","author":"S Braune","year":"2018","unstructured":"Braune S, Grimm S, van H\u00f6vell P, Freudensprung U, Pellegrini F, Hyde R, et al. Comparative effectiveness of delayed-release dimethyl. Fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol. 2018;265(12):2980\u201392. https:\/\/doi.org\/10.1007\/s00415-018-9083-5.","journal-title":"J Neurol."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00775-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-020-00775-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00775-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T11:09:30Z","timestamp":1608289770000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-020-00775-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00775-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"5 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received no financial support for the design, data collection, data analysis, data interpretation, or writing. It did not interfere in the care received by patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"BP has received assistance for conference attendance from Merck and funding for academic training course from Genzyme. JS has received honoraria for lecturing, consulting or travel expenses from Biogen-Inc, Merck, Teva, Novartis, Roche and Sanofi-Genzyme. VG has received honoraria for speaking and subinvestigator in clinical trials from Genzyme, Novartis, Biogen Idec and Almiral. SSM has received funding for research projects or support as conference fees, mentoring, and assistance for conference attendance from Sanofi-Genzyme, Biogen, Roche, Merck-Serono, Novartis, Teva, Bayer, Almirall and Mylan. LCF has received funding for research projects as conference fees and assistance for conference attendance from Bayer, Biogen, Roche, Merck, Novartis, Almirall, Celgene, Biopas, Ipsen and Sanofi. COG has received speaker fees and\/or has served on the advisory boards of Biogen, Celgene, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. JMGD has received speaker fees or advisor honoraria from Biogen, Celgene, AbbVie, Sanofi, Almirall, Novartis, Roche, Teva and Merck. LB has received honoraria for lecturing, consulting or travel expenses from Bayer, Biogen-Idec, Merck, Teva, Novartis, Roche, Almirall and Genzyme. VML has received consulting or speaking fees from Almirall, Biogen, Genzyme, Merck Serono, Novartis, Roche, Terumo, Sanofi, Teva and Celgene. CM has received assistance for conference attendance from Novartis, Biogen Idec, Merck. IC has received funding for travel or speaker honoraria from Bayer, Biogen, Genzyme, Merck, Novartis, Roche, Sanofi and Teva, and research support from Teva. CLS has received funding for travel or speaker honoraria from Biogen, Genzyme and Novartis, and research support from Teva. ERG has received honoraria for lecturing or assistance for conference attendance from Bayer, Biogen, Merck, Teva, Novartis, Roche, Almirall and Sanofi-Genzyme. YA has received funding for research projects, conference fees, mentoring and assistance for conference attendance from Teva, Merck, Biogen, Roche, Merck, Novartis, Almirall and Sanofi. JPC has received funding for research projects from Biogen, and assistance for conference attendance from Biogen, Roche and Sanofi. MLM has received compensation for consulting and speaking fees from Merck, Biogen, Novartis, Sanofi-Genzyme, Almirall, Bayer, Roche and Teva. AO has received honoraria for lecturing, consulting or travel expenses from Merck, Biogen-Idec, Sanofi, Novartis, Bayer, Roche, Almirall and Teva. IMT has received honoraria for lecturing or assistance for conference attendance from Bayer, Biogen, Merck, Teva, Novartis, Roche, and Genzyme, and research grants from Novartis. IT, MGM, JDD, ALR, AC, PS, LA, HM, CAV, RB, JAGM, SU, LR, PP, PS y RG declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/competing interests"}},{"value":"This study was approved by The Ethical Committee of the Getafe University Hospital (Madrid, Spain), the Coordinator Center of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from each participant.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Qualified researchers may request access to study protocol, statistical analysis and patient level data. Patient\u2019s data will be anonymized in order to protect the privacy of the participants.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Design\/conceptualization of the study: YA, BP, JS, VG, JAGM. Analysis\/interpretation of the data: YA, BP, IT, CA. Drafting and revising the manuscript: YA, JS, BP, COG, JAGM. Statistical analysis: YA, BP, IT, CA. Acquisition of data and revising the manuscript for intellectual content: all authors. All authors give final approval of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}